Pulmonary Arterial Hypertension (PAH) Group 1: Overview, Workup, Risk Stratification, and Current (and Future) Treatment Approaches

Author:

Yaqoob Maidah1,DeCato Thomas W.23,Oudiz Ronald34

Affiliation:

1. Division of Pulmonary & Critical Care Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA

2. Division of Respiratory & Critical Care Physiology & Medicine, Harbor-UCLA Medical Center, Torrance, CA, USA

3. The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA, USA

4. Division of Cardiology, Harbor- UCLA Medical Center, Torrance, CA, USA

Abstract

Abstract: Risk assessment (or risk stratification) and both current and future therapies for pulmonary arterial hypertension (PAH) will be discussed in part B. Risk assessment is key in the initial evaluation and follow-up of persons with PAH. Risk assessment provides information on disease severity and mortality, which, over time, have been incorporated into the application of PAH therapies. After the initial risk assessment, a 4-strata approach is recommended at subsequent follow- up evaluations by the 2022 ERS/ESC pulmonary hypertension (PH) guidelines as described initially in COMPERA 2.0. This method appears to have increased sensitivity to changes in risk from baseline to follow-up and to changes in long-term mortality risk. Current PAH therapies target the prostacyclin, endothelin, and nitric oxide pathways. A sequential approach to therapy has been recommended since publication of the 2009 guidelines and, in the most recent iteration incorporates the 4-strata approach at follow-up. Additional therapy is recommended when intermediate- high or high-risk status is present. New therapies are under active investigation that include targeting novel pathways. Sotatercept, a fusion protein that binds to and sequesters select transforming growth factor β superfamily ligands, is the most promising novel therapy at this time. A recent phase 3, randomized, double-blind, placebo-controlled study in group 1 PAH patients showed a statistically significant improvement in 6-minute walk distance and additional studies of this drug in PH populations are ongoing. Progress in phenotyping this heterogeneous disease is being made, and as PAH therapies continue to evolve, the use of personalized treatment regimens may be possible in the care of this complex, and highly morbid and mortal disease.

Publisher

Bentham Science Publishers Ltd.

Reference130 articles.

1. Humbert M.; Kovacs G.; Hoeper M.M.; Badagliacca R.; Berger R.M.F.; Brida M.; Carlsen J.; Coats A.J.S.; Escribano-Subias P.; Ferrari P.; Ferreira D.S.; Ghofrani H.A.; Giannakoulas G.; Kiely D.G.; Mayer E.; Meszaros G.; Nagavci B.; Olsson K.M.; Pepke-Zaba J.; Quint J.K.; Rådegran G.; Simonneau G.; Sitbon O.; Tonia T.; Toshner M.; Vachiery J.L.; Vonk Noordegraaf A.; Delcroix M.; Rosenkranz S.; 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2023,61(1),2200879

2. Barst R.J.; Chung L.; Zamanian R.T.; Turner M.; McGoon M.D.; Functional class improvement and 3-year survival outcomes in patients with pulmonary arterial hypertension in the REVEAL Registry. Chest 2013,144(1),160-168

3. Galiè N.; Humbert M.; Vachiery J.L.; Gibbs S.; Lang I.; Torbicki A.; Simonneau G.; Peacock A.; Vonk Noordegraaf A.; Beghetti M.; Ghofrani A.; Gomez Sanchez M.A.; Hansmann G.; Klepetko W.; Lancellotti P.; Matucci M.; McDonagh T.; Pierard L.A.; Trindade P.T.; Zompatori M.; Hoeper M.; 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2016,37(1),67-119

4. Galiè N.; Channick R.N.; Frantz R.P.; Grünig E.; Jing Z.C.; Moiseeva O.; Preston I.R.; Pulido T.; Safdar Z.; Tamura Y.; McLaughlin V.V.; Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J 2019,53(1),1801889

5. D’Alonzo G.E.; Barst R.J.; Ayres S.M.; Bergofsky E.H.; Brundage B.H.; Detre K.M.; Fishman A.P.; Goldring R.M.; Groves B.M.; Kernis J.T.; Levy P.S.; Pietra G.G.; Reid L.M.; Reeves J.T.; Rich S.; Vreim C.E.; Williams G.W.; Wu M.; Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991,115(5),343-349

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3